July 23, 2024 — Liver disease is frighteningly common worldwide. Metabolic dysfunction-associated steatotic liver disease, or MASLD, is an umbrella term describing conditions related to a buildup of fat in the liver. Formerly known as nonalcoholic fatty liver disease, this condition affects 1 in 4 people worldwide. Among those with type 2 diabetes, insulin resistance, obesity, or all three, […]
June 6, 2024 — On the opening day of the EASL Congress in Milan, we got a peek at more details on the results of the phase 2 study of tirzepatide in MASH (metabolic dysfunction associated steatohepatitis). The study, called SYNERGY-NASH, will be the subject of a late-breaking presentation on Saturday at the meeting. But the release of the […]
May 9, 2024 — We’re packing our bags for Venice, where the European Congress on Obesity (ECO 2024) will start in just a few days. A lot will be coming at us in a short space of time, so taking time to set some priorities is essential. Thus, we have a short list of things that we’ll be seeking […]
March 21, 2024 — For an early stage of hepatic steatosis called MASLD, JAMA has just published results from an intriguing study. It is a small RCT showing that low-dose aspirin can significantly reduce fat in the liver of persons with MASLD and without cirrhosis. MASLD is a new acronym for metabolic dysfunction-associated steatotic liver disease. You might know […]
December 4, 2023 — By the end of this month, we will be seeing lists of what’s in and what’s out for the coming year. For people whose minds drift toward liver disease, we have an entry. Fatty liver is out and steatotic liver is in. NAFLD goes to the dustbin, replaced by MASLD, while MASH takes over from […]
